Solution phase synthesis of oligonucleotides
View Patent ↗A process for the synthesis in solution phase of a phosphorothioate triester is provided. The process comprises the solution phase coupling of an H-phosphonate with an alcohol in the presence of a coupling agent to form an H-phosphonate diester. The H-phosphonate diester is oxidised in situ with a sulfur transfer agent to produce the phosphorothioate triester. Preferably, the H-phosphonate and alcohol are protected nucleosides or oligonucleotides. Oligonucleotide H-phosphonates which can be used in the formation of phosphorothioate triesters are also provided.
1. In an improved process for the synthesis of a deprotected oligonucleotide, said process comprising
assembling a protected phosphorothioate triester oligonucleotide,
deprotecting the phosphorothioate triester oligonucleotide to form a deprotected phosphodiester oligonucleotide, deprotected phosphorothioate oligonucleotide, or a deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages,
the improvement being that said assembling comprises
solution phase coupling, in the presence of a coupling agent,
(i) a protected nucleoside or oligonucleotide H-phosphonate comprising a 3′- or 5′H-phosphonate function; with
(ii) a protected nucleoside or oligonucleotide comprising a free 3′- or 5′-hydroxy function;
to form an H-phosphonate diester and, in situ,
reacting the H-phosphonate diester with a sulfur transfer agent to produce said phosphorothioate triester.
2. The process of claim 1 , further comprising purifying said deprotected phosphodiester oligonucleotide deprotected phosphorothioate oligonucleotide, or deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages.
3. The process of claim 1 , comprising forming said deprotected phosphodiester oligonucleotide.
4. The process of claim 1 , comprising forming said deprotected phosphorothioate oligonucleotide.
5. The process of claim 1 , comprising forming said deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages.
6. A The process of claim 1 , comprising coupling a protected nucleoside or oligonucleotide H-phosphonate comprising a 3′-H-phosphonate function with a protected nucleoside or oligonucleotide comprising a free 5′-hydroxy function.
7. The process of claim 1 , wherein said coupling agent is a diaryl phosphorochloridate represented by formula (ArO) 2 POCl, wherein Ar represents phenyl, 2-chlorophenyl, 2,4,6-trichlorophenyl, or 2,4,6-tribromophenyl.
8. The process of claim 1 , wherein said sulfur transfer agent is represented by the following formula:
wherein
L represents a leaving group, and
A represents an aryl group, a methyl group, a substituted alkyl group or an alkenyl group.
9. The process or claim 8 , wherein
L represents a morpholine-3,5-dione, a phthalimide, a succinimide, a maleimide, or an indazole, and
A represents a 4-halophenyl group, a 4-alkylphenyl group, a methyl group, a benzyl group, an alkylbenzyl group, a halobenzyl group, an ally group, a crotyl group, a 2-cyanoethyl group, or a 2-(4-nitrophenyl)ethyl group.
10. The process of claim 1 , wherein said protected nucleoside or oligonucleotide H-phosphonate comprising a 3′- or 5′-H-phosphonate function and said protected nucleoside or oligonucleotide comprising a flee 3′- or 5′-hydroxy function are selected from the group consisting of deoxyribonucleosides, oligodeoxyribonucleotides, ribonucleosides, 2′-O-(alkyl, alkoxyalkyl or alkenyl)-ribonucleosides, oligoribonucleotides, and 2′-O-(alkyl, alkoxyslkyl or alkenyl)-oligoribonucleotides.
11. In an improved process for the synthesis of a deprotected oligonucleotide, said process comprising
assembling a protected phosphorothioate triester oligonucleotide,
deprotecting the phosphorothioate triester oligonucleotide to form a deprotected phosphodiester oligonucleotide, deprotected phosphorothioate oligonucleotide, or a deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages,
the improvement being that said assembling comprises
solution phase coupling
(i) a protected nucleoside or oligonucleotide H-phosphonate comprising a 3′-H-phosphonate function;
with
(ii) a protected nucleoside or oligonucleotide comprising a free 5′-hydroxy function;
to form an H-phosphonate diester and, in situ,
reacting the H-phosphonate diester with a sulfur transfer agent to produce said phosphorothioate triester
wherein said solution phase coupling is performed in the presence of a diaryl phosphorochloridate represented by formula (ArO) 2 POCl, wherein Ar represents phenyl, 2-chlorophenyl, 2,4,6-trichlorophenyl, or 2,4,6-tribromophenyl, and
wherein said sulfur transfer agent is represented by the following formula
wherein
L represents a leaving group, and
A represents an aryl group, a methyl group, a substituted alkyl group or an alkenyl group.
12. The process of claim 11 , comprising forming said deprotected phosphodiester oligonucleotide.
13. The process of claim 11 , comprising forming said deprotected phosphorothioate oligonucleotide.
14. The process of claim 11 , comprising forming said deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages.
15. The process of claim 11 , wherein
L represents a morpholine-3,5-dione, a phthalimide, a succinimide, a maleimide, or an indazole, and
A represents a 4-halophenyl group, a 4-alkylphenyl group, a methyl group, a benzyl group, an alkylbenzyl group, a halobenzyl group, an ally group, a crotyl group, a 2-cyanoethyl group, or a 2-(4-nitrophenyl)ethyl group.
16. The process of claim 11 , wherein said protected nucleoside or oligonucleotide H-phosphonate comprising a 3′-H-phosphonate function and said protected nucleoside or oligonucleotide comprising a free 5′-hydroxy function are selected from the group consisting of deoxyribonucleosides, oligodeoxyribonucleotides, ribonucleosides, 2′-O-(alkyl, alkoxyalkyl or alkenyl)-ribonucleosides, oligoribonucleotides, and 2′-O-(alkyl, alkoxyalkyl or alkenyl)-oligoribonucleotides.
17. The process of claim 11 , further comprising purifying said deprotected phosphodiester oligonucleotide, deprotected phosphorothioate oligonucleotide, or deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages.
18. In an improved process for the synthesis of a purified, deprotected oligonucleotide, said process comprising
assembling a protected phosphorothioate triester oligonucleotide,
deprotecting the phosphorothioate triester oligonucleotide to form a deprotected phosphodiester oligonucleotide, deprotected phosphorothioate oligonucleotide, or a deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages,
purifying said deprotected phosphodiester oligonucleotide, deprotected phosphorothioate oligonucleotide, or deprotected oligonucleotide comprising both phosphodiester and phosphorothioate diester internucleotide linkages,
the improvement being that said assembling comprises
solution phase coupling
(i) a protected nucleoside or oligonucleotide H-phosphonate comprising a 3′-H-phosphonate function;
with
(ii) a protected nucleoside or oligonucleotide comprising a free 5′-hydroxy function;
to form an H-phosphonate diester and, in situ,
reacting the H-phosphonate diester with a sulfur transfer agent to produce said phosphorothioate triester
wherein said solution phase coupling is performed in the presence of a diaryl phosphorochloridate represented by formula (ArO) 2 POCl, wherein Ar represents phenyl, 2-chlorophenyl, 2,4,6-trichlorophenyl, or 2,4,6-tribromophenyl, and
wherein said sulfur transfer agent is represented by the following formula
wherein
L represents a leaving group, and
A represents an aryl group, a methyl group, a substituted alkyl group or an alkenyl group.
19. The process of claim 18 , wherein said protected nucleoside or oligonucleotide H-phosphonate comprising a 3′-H-phosphonate function and said protected nucleoside or oligonucleotide comprising a free 5′-hydroxy function are selected from the group consisting of deoxyribonucleosides, oligodeoxyribonucleotides, ribonucleosides, 2′-O-alkyl, alkoxyalkyl or alkenyl),ribonucleosides, oligoribonucleotides, and 2′-O-(alkyl, alkoxyslkyl or alkenyl)-oligoribonucleotides.
20. The process of claim 15 , wherein
L represents a morpholine-3,5-dione, a phthalimide, a succinimide, a maleimide, or an indazole, and
A represents a 4-halophenyl group, a 4-alkylphenyl group, a methyl group, a benzyl group, an alkylbenzyl group, a halobenzyl group, an ally group, a crotyl group, a 2-cyanoethyl group, or a 2-(4-nitrophenyl)ethyl group.